KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Acquisitions Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances

Daily Values

Growth Metrics

Merck (MRK) Free Cash Flow (2016 - 2026)

Merck has reported Free Cash Flow over the past 18 years, most recently at $2.9 billion for Q1 2026.

Quarterly Free Cash Flow rose 149.74% to $2.9 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $14.1 billion through Mar 2026, down 17.16% year-over-year, with the annual reading at $12.4 billion for FY2025, 31.7% down from the prior year.
Free Cash Flow was $2.9 billion for Q1 2026 at Merck, up from $1.8 billion in the prior quarter.
Over five years, Free Cash Flow peaked at $8.5 billion in Q3 2024 and troughed at -$743.0 million in Q4 2023.
The 5-year median for Free Cash Flow is $2.9 billion (2026), against an average of $3.4 billion.
Year-over-year, Free Cash Flow skyrocketed 2290.51% in 2022 and then crashed 122.65% in 2023.
A 5-year view of Free Cash Flow shows it stood at $3.3 billion in 2022, then crashed by 122.65% to -$743.0 million in 2023, then skyrocketed by 438.22% to $2.5 billion in 2024, then fell by 27.42% to $1.8 billion in 2025, then surged by 60.47% to $2.9 billion in 2026.
Per Business Quant, the three most recent readings for MRK's Free Cash Flow are $2.9 billion (Q1 2026), $1.8 billion (Q4 2025), and $6.8 billion (Q3 2025).